Appendix 1
Use and doses of long-term inhaled bronchodilator and corticosteroids determined in response trials
Response | Drug | Dose (mcg) | Frequency | Delivery |
Improved airway function Improved exercise capacity Reduced breathlessness Improved quality of life |
beta-agonist | |||
Salbutamol | 100-200mcg | 4-6-hourly | MDI/spacer | |
Salbutamol | 200-400mcg | 4-6-hourly | DPI | |
Terbutaline | 500-1500mcg | 6-8-hourly | DPI | |
Salmeterol | 50mcg | 12-hourly | MDI/DPI | |
Formoterol | 12mcg | 12-hourly | MDI/DPI | |
Indacaterol | 150-300mcg | 24-hourly | DPI | |
Anticholinergic (Antimuscarinic) |
||||
Ipratropium | 42-84mcg | 6-8-hourly | MDI/spacer | |
Tiotropium | 18mcg | 24-hourly | DPI | |
Tiotropium | 2.5mcg | 24-hourly | Respimat | |
Glycopyrronium | 50mcg | 24-hourly | DPI | |
Corticosteroid | Inhaled | |||
Beclometasone (small particle) |
50-200mcg/day | 12-hourly | MDI/spacer | |
Budesonide | 400mcg | 12-hourly | DPI | |
Fluticasone propionate | 250-500mcg/day | 12-hourly | MDI/DPI | |
Fluticasone furoate | 100mcg/day | 12-hourly | DPI | |
Ciclesonide | 80-320mcg/day | 24-hourly | MDI – spacer not recommended | |
MDI=metered dose inhaler. DPI=dry powder inhaler. |